<DOC>
	<DOCNO>NCT01610336</DOCNO>
	<brief_summary>This study ass safety efficacy escalate dos INC280 add gefitinib patient lung cancer know dysregulation c-MET pathway fail benefit prior treatment either gefitinib erlotinib .</brief_summary>
	<brief_title>A Safety Efficacy Study INC280 Gefitinib Patients With EGFR Mutated , c-MET-amplified NSCLC Who Have Progressed After EGFRi Treatment</brief_title>
	<detailed_description>Patients treat INC280 gefitinib ( 250mg ) daily . Dose escalation INC280 perform . Each cohort phase IB part consist 3 6 newly enrol patient . A twice daily administration INC280 may investigate deemed appropriate base emerge result ongoing clinical trial .</detailed_description>
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<mesh_term>Gefitinib</mesh_term>
	<criteria>Documented EGFR mutation Documented cMET dysregulation Prior clinical benefit EGFR inhibitor subsequent progression ≥ 18 year old Life expectancy ≥ 3 month ECOG performance status ≤ 2 Unable swallow table twice daily Previous treatment cMET inhibitor Any unresolved toxicity form previous anticancer therapy great grade 1 History cystic fibrosis History acute chronic pancreatitis Unable undergo MRI CT sans Known history HIV Undergone bone marrow solid organ transplant Clinically significant wound lung tumor lesion increase likelihood bleeding Pregnant nursing Other protocoldefined inclusion/exclusion criterion may apply</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>EGFR</keyword>
	<keyword>c-MET</keyword>
	<keyword>Lung cancer</keyword>
	<keyword>Gefitinib</keyword>
	<keyword>Erlotinib</keyword>
</DOC>